干细胞治疗市场 - 全球产业规模、份额、趋势、机会和预测，2018-2028F 按类型、细胞来源、按应用、最终用户、地区、竞争细分

2022 年全球干细胞治疗市场价值为 2.631 亿美元，预计在预测期内将呈现强劲增长，到 2028 年复合年增长率为 9.8%。干细胞治疗也称为再生医学，可促进细胞的修復反应。透过利用干细胞或其衍生物来治疗生病、功能障碍或受伤的组织。它代表了器官移植的下一阶段，以细胞取代有限的供体器官。干细胞具有在人体内分化成各种细胞类型的能力，起到恢復机制的作用。干细胞主要有两种分类：胚胎干细胞和成体干细胞。干细胞进一步分为两大类：多能性细胞和专能细胞。源自胚胎或胎儿组织的多能干细胞进行复製，并有助于中胚层、外胚层和内胚层（三个初级胚层）内细胞和组织的发育。

主要市场驱动因素：

干细胞治疗技术不断进步：

市场概况
预测期	2018-2028
2022 年市场规模	26107万美元
2028 年市场规模	5.3344亿美元
2023-2028 年复合年增长率	12.39%
成长最快的细分市场	同种异体移植
最大的市场	北美洲

干细胞分离、扩增和分化技术的进步促进了干细胞疗法的进步。科学家目前正在探索不同来源的干细胞，包括胚胎干细胞、诱导性多能干细胞（iPSC）和成体干细胞。此外，基因编辑（例如 CRISPR）等新兴技术有望提高干细胞治疗的精确度和有效性。人们对干细胞疗法的认识和可用性不断提高，导致对创新和系统开发的需求不断增加。市场参与者正在积极寻求合作，以加强其研发活动，旨在扩大发展中国家和已开发国家的干细胞治疗市场。大量资金投入细胞为基础的研究，特别是诱导多能干细胞领域。该技术涉及对成人干细胞进行基因重编程以获得胚胎样干细胞，成为市场上可行的替代方案。

干细胞治疗需求激增

干细胞疗法由于其在再生医学中的潜力而获得了相当大的关注和接受。它为治疗各种疾病提供了希望，包括神经系统疾病、心血管疾病、骨科损伤和自体免疫疾病。干细胞研究持续成长，导致监管机构批准的数量增加。因此，干细胞治疗市场在过去经历了显着成长，预计在预测期内将继续成长。该领域正在进行的研究和开发活动也刺激了利用干细胞进行基因和细胞治疗的需求。此外，註册临床试验数量的增加可能会对市场需求产生相当大的影响并推动销售成长。

增加政府对研发活动的支持

在已开发国家和其他购买力强劲的国家，对创新药物的需求预计在未来几年将显着成长。这些药物有望治疗各种疾病，包括心血管、神经和自体免疫疾病。由于这些疾病在全球范围内的盛行率不断增加，干细胞治疗或疗法的市场预计将扩大。在资金增加的推动下，市场过去也出现了成长。虽然在治疗中使用胚胎引起了伦理问题，但重要的是要承认它们在拯救生命方面的潜力。持续的开发努力产生了创新疗法。 iPSC 被世界各地的研究人员广泛用于进行癌症研究。该产品已用于针对帕金森氏症和阿兹海默症等疾病的临床试验，预计未来几年市场将会成长。在大流行期间，研究人员专注于开发对抗 COVID-19 病毒的治疗方法，其中干细胞的使用显示出了前景。为了加强干细胞市场的研究活动，澳洲政府进行了大量投资，并为未来十年提供了全面的路线图。

慢性疾病增加

慢性病是全球普遍存在的健康问题，影响着全球三分之一的成年人。这些病症包括一系列疾病，包括癌症、肌肉骨骼和神经系统疾病、慢性损伤以及心血管和胃肠道疾病。他们通常需要住院治疗、长期残疾、生活品质下降，甚至可能致命。

干细胞已被用于治疗病毒的各种临床试验，提供了改进的治疗选择并显着减少了病例数。此外，再生医学的使用可能在降低个体感染率方面发挥至关重要的作用。在临床试验增加和获得监管机构必要批准的推动下，预计未来几年该产品的需求将会成长。随着全球慢性病盛行率的上升，对干细胞治疗的需求预计将扩大，未来将带来有利的市场机会。

主要市场挑战

高成本治疗

开发和实施干细胞疗法涉及大量研究、临床试验和製造成本。研究、开发和生产相关的高成本可能会限制患者的可及性。细胞处理市场的扩张因其高成本而受到阻碍。随着人们寻求最新的治疗选择，细胞治疗作为一种治疗选择越来越受欢迎。儘管需求显着增加，细胞治疗仍然昂贵得令人望而却步。光是关节注射一项的费用就高达 1,000 美元，而更复杂的手术可能高达 10 万美元。在美国，预计 2020 年每位患者干细胞治疗的平均费用将在 4,000 美元至 8,000 美元之间。因此，干细胞治疗市场的成长受到治疗成本上涨的限制。

与现有疗法的竞争

干细胞疗法可能需要证明其优于现有疗法，才能获得医疗专业人员、保险公司和监管机构的认可。干细胞疗法通常被认为是各个医学领域现有疗法的潜在替代品或补充品。虽然干细胞前景广阔，但它们也面临着与成熟治疗方法的竞争和比较。干细胞疗法需要严格的测试和监管批准，以确保患者安全。干细胞不可预测的行为以及对肿瘤形成或免疫反应等潜在副作用的担忧，构成了在广泛采用之前必须解决的挑战。

主要市场趋势

增加临床试验和研究

干细胞治疗领域的临床试验和研究可能会持续成长。随着科学家更了解干细胞行为并优化其使用，将产生更多证据来支持其对各种医疗状况的功效和安全性。正在进行的研究可能会揭示干细胞疗法在各种医疗条件下的新的、多样化的应用。随着对干细胞的了解加深，科学家可能会发现以前未被认识到的治疗机会。

国际合作

全球研究人员和机构之间的合作可以加速干细胞研究的进展。共享知识和资源可以带来更快的进步和突破。干细胞研究的进步可能会带来更精确和个人化的治疗。透过根据个别患者的具体需求和基因组成来客製化治疗方案，研究人员可以增强治疗效果并最大程度地降低潜在风险。临床试验的成功结果可以吸引投资并导致干细胞疗法的商业开发。这可以使这些治疗方法更广泛地为患者提供。

细分市场洞察

类型洞察

同种异体移植领域透过移植供体细胞为患者建立新的免疫系统，在 2022 年实现了最高的市场收入。这种治疗方法为各种恶性和非癌性疾病提供了潜在的治疗方法，包括急性白血病、慢性白血病、何杰金氏淋巴瘤、肾上腺脑白质营养不良、骨髓衰竭症候群等。

细胞来源洞察

脂肪组织来源的间质干细胞细分市场将成为 2022 年的主要收入贡献者，预计将在整个预测期内保持其在干细胞治疗市场的主导地位。这可以归因于癌症患者数量的不断增加、目标人口的扩大、有害辐射暴露的增加以及政府的倡议。相反，由于肌肉骨骼疾病等慢性和致命疾病的发病率上升，以及吸烟（包括被动吸烟）的增加，预计骨髓间质干细胞细分市场在预测期内将呈现最高的市场增长。与癌症有关

区域洞察

根据区域分析，2022年北美地区在干细胞治疗市场中占据最大份额。北美地区的主导地位可归因于该地区主要市场参与者的存在、先进的医疗基础设施、有前途的报销和政府政策，以及提高人们对干细胞疗法的认识。这些因素促进了该地区干细胞治疗市场的成长。此外，由于旨在开发先进疗法并为医疗保健专业人员和危重疾病患者提供更好解决方案的研发活动不断增加，投资者对北美干细胞治疗市场高度感兴趣。

在中国、日本和印度等国家合作投资该市场的新兴製药公司的推动下，亚太地区预计将成为下一个最大的成长市场。该地区也见证了小型新创公司进入干细胞治疗市场。正在进行的大规模临床试验和该地区干细胞库的存在预计将进一步扩大该市场的全球足迹。预计欧洲将成为市场下一个最大的地区。

主要市场参与者

• 生物修復疗法公司
• 新基公司
• ReNeuron 集团有限公司
• Opexa 治疗公司
• Pluristem 治疗公司
• 干细胞科技公司
• 生物库家族
• 珍贵细胞国际有限公司
• 中胚层有限公司
• 塞内卡生物製药股份有限公司

可用的客製化：

全球干细胞治疗市场报告根据给定的市场资料，技术科学研究根据公司的具体需求提供客製化服务。该报告可以使用以下自订选项：

公司资讯

• 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：服务概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球干细胞治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依类型（同种异体移植、自体移植）
  • 依细胞来源分类（脂肪组织来源的间质干细胞、骨髓来源的间质干细胞、脐带血/胚胎干细胞）
  • 按应用（癌症、肌肉骨骼疾病、伤口和损伤、心血管疾病、其他）
  • 按最终使用者（医院和外科中心、治疗公司）
  • 按地区
  • 按公司划分 (2022)
• 市场地图

第 6 章：北美干细胞治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型
  • 按细胞来源
  • 按应用
  • 按最终用户
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第 7 章：欧洲干细胞治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型
  • 按细胞来源
  • 按应用
  • 按最终用户
  • 按国家/地区
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太干细胞治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型
  • 按细胞来源
  • 按应用
  • 按最终用户
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲干细胞治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型
  • 按应用
  • 按细胞来源
  • 按最终用户
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲干细胞治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型
  • 按细胞来源
  • 按应用
  • 按最终用户
  • 按国家/地区
• MEA：国家分析
  • 南非干细胞疗法
  • 沙乌地阿拉伯干细胞疗法
  • 阿联酋干细胞疗法

第 11 章：市场动态

第 12 章：市场趋势与发展

第 13 章：全球干细胞治疗市场：SWOT 分析

第14章：竞争格局

• 商业概览
• 应用程式产品
• 最近的发展
• 主要人员
• SWOT分析
  • Biorestorative Therapies Inc.
  • Celgene corporation
  • ReNeuron Group plc
  • Opexa Therapeutics, Inc.
  • Pluristem Therapeutics Inc
  • STEMCELL Technologies Inc.
  • Biovault family
  • Precious Cells International Ltd
  • Mesoblast Ltd
  • Seneca Biopharmaceuticals, Inc.

第 15 章：策略建议

第 16 章：关于我们与免责声明

The global stem cell therapy market was valued at USD 263.10 million in 2022 and is expected to demonstrate robust growth in the forecast period, with a CAGR of 9.8% through 2028. Stem cell therapy, also known as regenerative medicine, facilitates the repair response of diseased, dysfunctional, or injured tissue through the utilization of stem cells or their derivatives. It represents the next phase in organ transplantation, substituting limited availability of donor organs with cells. Stem cells have the ability to differentiate into various cell types within the human body, functioning as a restorative mechanism. There are two primary classifications of stem cells: embryonic stem cells and adult stem cells. Stem cells are further categorized into two major groups: pluripotent and multipotent. Pluripotent stem cells, derived from embryos or fetal tissues, undergo replication and contribute to the development of cells and tissues within the mesoderm, ectoderm, and endoderm-the three primary germ layers.

Key Market Drivers:

Increasing Technological Advancement in Stem Cell Therapeutics:

Market Overview
Forecast Period	2018-2028
Market Size 2022	USD 261.07 Million
Market Size 2028	USD 533.44 Million
CAGR 2023-2028	12.39%
Fastest Growing Segment	Allogenic Transplants
Largest Market	North America

The progress of stem cell therapies has been facilitated by advancements in stem cell isolation, expansion, and differentiation techniques. Scientists are currently exploring different sources of stem cells, including embryonic stem cells, induced pluripotent stem cells (iPSCs), and adult stem cells. Furthermore, emerging technologies such as gene editing (e.g., CRISPR) hold promise for improving the precision and effectiveness of stem cell-based treatments. The growing awareness and availability of stem cell therapies have led to an increasing demand for innovation and system development. Market players are actively seeking collaborations to enhance their research and development activities, aiming to expand the stem cell treatment market in both developing and developed nations. Substantial funding has been invested in cell-based research, particularly in the field of induced pluripotent stem cells. This technique involves genetic reprogramming of adult human stem cells to obtain embryonic-like stem cells, serving as a viable alternative in the market.

Surging Demand for Stem Cell Therapy

Stem cell therapy has garnered considerable attention and acceptance owing to its potential in regenerative medicine. It offers promise in the treatment of various conditions, including neurological disorders, cardiovascular diseases, orthopedic injuries, and autoimmune disorders. There has been a consistent growth in stem cell research, leading to an increase in approvals from regulatory authorities. Consequently, the market for stem cell therapy has experienced significant growth in the past and is expected to continue growing during the forecast period. Ongoing research and development activities in the field have also spurred demand for gene and cell treatments utilizing stem cells. Furthermore, the rising number of registered clinical trials is likely to have a considerable impact on market demand and drive sales growth.

Increasing in Government Support for Research and Development Activities

In developed nations and other countries with strong purchasing power, the demand for innovative medicines is expected to experience significant growth in the coming years. These medicines hold promise for the treatment of various disorders, including cardiovascular, neurological, and autoimmune conditions. The market for stem cell treatment or therapy is projected to expand due to the increasing prevalence of these diseases worldwide. The market has also witnessed growth in the past, fueled by heightened funding. While using embryos in treatment raises ethical concerns, it is important to acknowledge their potential in saving lives. Continuous and development efforts have yielded innovative therapies. iPSCs are widely utilized by researchers worldwide to conduct studies on cancer. This product has been employed in clinical trials targeting diseases such as Parkinson's and Alzheimer's, leading to a projected market growth in the coming years. During the pandemic, researchers focused on developing treatments for combating the COVID-19 virus, with the use of stem cells showing promise. To enhance research activities in the stem cell market, the Australian government has made significant investments and provided a comprehensive roadmap for the next decade.

Rising Chronic Disorders

Chronic diseases are prevalent health issues globally, affecting one out of every three adults worldwide. These conditions encompass a range of ailments including cancer, musculoskeletal and neurologic disorders, chronic injuries, and cardiovascular and gastrointestinal diseases. They often necessitate hospitalization, long-term disability, diminished quality of life, and can even be fatal.

Stem cells have been utilized in various clinical trials for treating the virus, offering improved treatment options and significantly reducing the number of cases. Furthermore, the use of regenerative medicines may play a vital role in decreasing the infection rate among individuals. Anticipated growth in demand for this product is expected in the upcoming years, driven by an increase in clinical trials and obtaining necessary approvals from regulatory authorities. With a rising prevalence of chronic diseases worldwide, the demand for stem cell therapy is projected to expand, presenting favorable market opportunities in the future.

Key Market Challenges

High-Cost Treatment

Developing and implementing stem cell therapies involves significant research, clinical trials, and manufacturing costs. The high costs associated with research, development, and production can limit accessibility for patients. The expansion of the cell treatment market has been hindered by its high cost. As individuals seek out the latest therapeutic options, cell treatments have gained popularity as a treatment choice. Despite the significant increase in demand, cell treatments remain prohibitively expensive. Joint injections alone can cost up to USD1,000, while more complex procedures may reach up to USD100,000. In the United States, the average cost of stem cell therapy is projected to range between USD4,000 and USD8,000 per patient in 2020. Consequently, the growth of the stem cell therapy market is constrained by the elevated cost of treatment.

Competition with Established Therapies

Stem cell therapies may need to demonstrate superiority over existing treatments to gain acceptance from medical professionals, insurers, and regulatory bodies. Stem cell therapies are often considered as potential alternatives or complements to established therapies in various medical fields. While stem cells hold great promise, they also face competition and comparisons with well-established treatment approaches. Stem cell therapies require rigorous testing and regulatory approval to ensure patient safety. The unpredictable behavior of stem cells and concerns about potential side effects, such as tumor formation or immune responses, pose challenges that must be addressed before widespread adoption.

Key Market Trends

Increased Clinical Trials and Research

The field of stem cell therapy is likely to see continued growth in clinical trials and research studies. As scientists better understand stem cell behavior and optimize their use, more evidence will be generated to support their efficacy and safety for various medical conditions. Ongoing research will likely reveal new and diverse applications for stem cell therapy across various medical conditions. As the understanding of stem cells expands, scientists may identify previously unrecognized opportunities for treatment.

International Collaboration

Collaboration among researchers and institutions on a global scale could accelerate progress in stem cell research. Shared knowledge and resources could lead to faster advancements and breakthroughs. Advances in stem cell research could lead to more precise and personalized therapies. By tailoring treatments to individual patients based on their specific needs and genetic makeup, researchers can enhance therapeutic outcomes and minimize potential risks. Successful outcomes from clinical trials could attract investment and lead to the commercial development of stem cell therapies. This could make these treatments more widely available to patients.

Segmental Insights

Type Insights

The allogenic transplants segment achieved the highest market revenue in 2022 by establishing a new immune system for patients through engraftment of donor cells. This therapeutic approach offers potential treatment for various malignant and non-cancerous disorders including acute leukemia, chronic leukemia, Hodgkin's lymphoma, adrenoleukodystrophy, bone marrow failure syndromes, and more.

The rising number of cancer patients has stimulated the demand for Omidubicel, an advanced cell therapy specifically designed for individuals with blood cancer. Notably, in 2022, the Managing Director of Duke Cancer Institute acknowledged the efficacy of allogenic stem cell transplant using the novel cell therapy Omidubicel in a phase 3 trial (NCT02730299), surpassing the standard myeloablative umbilical cord blood treatment.

The growth of this segment can be attributed to factors such as cost-effectiveness and the expansion of stem cell banking. Additionally, numerous cell therapy companies are redirecting their focus towards the development of allogenic cell therapy products, which is expected to further propel the expansion of this segment.

Cell Source Insights

The adipose tissue-derived mesenchymal stem cells segment emerged as the primary revenue contributor in 2022 and is expected to maintain its dominance throughout the forecast period in the stem cell therapy market. This can be attributed to the growing number of cancer patients, as well as the expanding target population, increased exposure to harmful radiation, and government initiatives. Conversely, the bone marrow-derived mesenchymal stem cells segment is projected to exhibit the highest market growth during the forecast period, driven by a higher incidence of chronic and fatal diseases like musculoskeletal disorders, and the rise in tobacco smoking, including passive smoking, which is associated with cancer

Regional Insights

Based on regional analysis, North America accounted for the largest share in the stem cell therapy market in 2022. The dominance of the North America region can be attributed to the presence of major market players in the region, advanced healthcare infrastructure, promising reimbursement and government policies, as well as increasing awareness about stem cell therapies among the population. These factors contribute to the growth of the stem cells therapy market in this region. Moreover, investors are highly attracted to the stem cells therapy market in North America due to the rising research and development activities aimed at developing advanced therapies and providing better solutions to healthcare professionals and patients with critical disorders.

The Asia Pacific region is expected to be the next largest growing market, driven by the presence of emerging pharmaceutical companies collaborating in countries such as China, Japan, and India to invest in this market. The region also witnesses the entry of small start-ups in the stem cell therapy market. Ongoing large-scale clinical trials and the presence of stem cell banks in the region are expected to further expand the market's global footprint. Europe is anticipated to be the next largest region in the market.

Key Market Players

• Biorestorative Therapies Inc.
• Celgene Corporation
• ReNeuron Group plc
• Opexa Therapeutics, Inc.
• Pluristem Therapeutics Inc
• STEMCELL Technologies Inc.
• Biovault family
• Precious Cells International Ltd
• Mesoblast Ltd
• Seneca Biopharmaceuticals, Inc.

Report Scope:

In this report, the Global Stem Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Stem Cell Therapy Market, By Type:

• Allogenic Transplants
• Autologous Transplants

Stem Cell Therapy Market, By Cell Source:

• Adipose Tissue-Derived Mesenchymal Stem Cells
• Bone Marrow-Derived Mesenchymal Stem Cells
• Cord Blood/Embryonic Stem Cells

Stem Cell Therapy Market, By Application:

• Cancer
• Musculoskeletal Disorder
• Wounds and Injuries
• Cardiovascular Disease
• Others

Stem Cell Therapy Market, By End User:

• Hospitals and Surgical Centres
• Therapeutic Companies

Stem Cell Therapy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Stem Cell Therapy Market.

Available Customizations:

Global Stem Cell Therapy Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Stem Cell Therapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Allogenic Transplants, Autologous Transplants)
  • 5.2.2. By Cell Source (Adipose Tissue-Derived Mesenchymal Stem Cells, Bone Marrow-Derived Mesenchymal Stem Cells, Cord Blood/Embryonic Stem Cells)
  • 5.2.3. By Application (Cancer, Musculoskeletal Disorder, Wounds and Injuries, Cardiovascular Disease, Others)
  • 5.2.4. By End User (Hospitals and Surgical Centres, Therapeutic Companies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2022)
• 5.3. Market Map

6. North America Stem Cell Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Cell Source
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Stem Cell Therapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Cell Source
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Stem Cell Therapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Cell Source
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Stem Cell Therapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Cell Source
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Stem Cell Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Cell Source
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Stem Cell Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Cell Source
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Stem Cell Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Cell Source
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Stem Cell Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Cell Source
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. France Stem Cell Therapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Cell Source
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Stem Cell Therapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Cell Source
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific Stem Cell Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Cell Source
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Stem Cell Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Cell Source
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Stem Cell Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Cell Source
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Stem Cell Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Cell Source
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Stem Cell Therapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Cell Source
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Stem Cell Therapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Cell Source
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America Stem Cell Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Cell Source
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Stem Cell Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Cell Source
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Stem Cell Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Cell Source
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Stem Cell Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Cell Source
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa Stem Cell Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Cell Source
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Stem Cell Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Cell Source
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Stem Cell Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Cell Source
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Stem Cell Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Cell Source
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

12. Market Trends & Developments

13. Global Stem Cell Therapy Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Application Offerings
• 14.3. Recent Developments
• 14.4. Key Personnel
• 14.5. SWOT Analysis
  • 14.5.1. Biorestorative Therapies Inc.
  • 14.5.2. Celgene corporation
  • 14.5.3. ReNeuron Group plc
  • 14.5.4. Opexa Therapeutics, Inc.
  • 14.5.5. Pluristem Therapeutics Inc
  • 14.5.6. STEMCELL Technologies Inc.
  • 14.5.7. Biovault family
  • 14.5.8. Precious Cells International Ltd
  • 14.5.9. Mesoblast Ltd
  • 14.5.10. Seneca Biopharmaceuticals, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer